Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ConvictionCHIK: Plasma Transfusion for Neonatal Chikungunya
NCT07190560Recruiting
- Sponsor
- CHU de La Réunion
- Start
- Aug 2027
- Primary completion
- Oct 2028
- Modality
- Biologic
- Countries
- 3
01
Overview
Open-label trial of PC-CHIK-V in chikungunya virus infection and encephalopathy (2 arms), sponsored by CHU de La Réunion. Primary endpoint: Proportion of newborns surviving without encephalitis/encephalopathy (EE) at 5 days. Planned start Aug 2027; status: recruiting.
02
Drugs
PC-CHIK-V
03
Conditions
chikungunya virus infectionencephalopathy
Beyond the preview
Go deeper on NCT07190560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190560.